Celgene Corp. Price Target Increased to $175.00 by Analysts at JMP Securities (CELG)
Stock analysts at JMP Securities hoisted their price objective on shares of Celgene Corp. (NASDAQ:CELG) from $160.00 to $175.00 in a report issued on Friday, AnalystRatings.Net reports. JMP Securities’ price objective suggests a potential upside of 12.37% from the stock’s previous close.
Other equities research analysts have also recently issued reports about the stock. Analysts at Credit Suisse raised their price target on shares of Celgene Corp. from $135.00 to $165.00 in a research note to investors on Friday. They now have a “neutral” rating on the stock. Separately, analysts at BMO Capital Markets raised their price target on shares of Celgene Corp. from $180.00 to $200.00 in a research note to investors on Friday. They now have an “outperform” rating on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Celgene Corp. in a research note to investors on Friday. They now have a $166.00 price target on the stock. Five investment analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $153.78.
Celgene Corp. (NASDAQ:CELG) traded down 1.41% during mid-day trading on Friday, hitting $155.74. The stock had a trading volume of 3,234,185 shares. Celgene Corp. has a 52 week low of $70.42 and a 52 week high of $151.00. The stock has a 50-day moving average of $142.3 and a 200-day moving average of $125.4. The company has a market cap of $64.052 billion and a price-to-earnings ratio of 44.17.
Celgene Corp. (NASDAQ:CELG) last announced its earnings results on Thursday, October 24th. The company reported $1.56 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.54 by $0.02. The company had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.64 billion. During the same quarter last year, the company posted $1.29 earnings per share. Celgene Corp.’s revenue was up 18.0% compared to the same quarter last year. On average, analysts predict that Celgene Corp. will post $5.98 earnings per share for the current fiscal year.
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.